RCM Technologies (RCMT) Q3 2024 earnings summary

Executive summary

• Third-quarter growth was driven by healthcare and engineering, with both segments ramping up in their end markets and new client wins supporting expansion.

• Revenue for the quarter ended September 28, 2024, increased 4% year-over-year to $60.4 million, with net income of $2.7 million, down from $3.8 million in the prior year period.

• Year-to-date revenue rose 4.8% to $201.5 million, while net income declined to $10.5 million from $11.6 million year-over-year.

• Life Sciences, Data, and Solutions division maintained high client retention and expanded service offerings, despite a decline in gross profit.

• Gross profit margin remained stable at 29.6% for the quarter and 28.9% year-to-date.

Financial highlights

• Consolidated gross profit for Q3 2024 grew 3.2% year-over-year to $17.8 million; year-to-date gross profit up 5.7% to $58.2 million.

• Adjusted EBITDA for Q3 increased 9.5% to $5.6 million; year-to-date Adjusted EBITDA up 10.5% to $19.6 million.

• Quarterly operating income was $4.4 million, flat year-over-year; year-to-date operating income was $16.0 million, up slightly.

• Healthcare gross profit rose 11.1%, engineering up 5.1%, while Life Sciences, Data, and Solutions declined 13.1% in Q3.

• Diluted EPS for the quarter was $0.35, down from $0.46; year-to-date diluted EPS was $1.31, down from $1.33.

Outlook and guidance

• Optimism for 20% school revenue growth for the 2024-2025 school year, driven by new and existing contracts.

• Management expects continued growth in school client revenue within Specialty Health Care, supported by recent investments in sales and recruiting.

• Engineering segment anticipated to benefit from strong Energy Services demand, though Industrial Processing and Aerospace remain volatile.

• Anticipation of attractive consolidated Adjusted EBITDA growth in Q4 2024 compared to fiscal 2023.

• Company believes liquidity and capital resources are sufficient for at least the next 12 months.